| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Short Communication |
1 Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51–59, D-63225 Langen, Germany
2 Robert Koch-Institut, Nordufer 20, D-13353 Berlin, Germany
Correspondence
Klaus Boller
bolkl{at}pei.de
 |
ABSTRACT |
|---|
 TOP ABSTRACT MAIN TEXTREFERENCES |
|---|
Present address: Forschungslabor Hautklinik Heidelberg, Vossstraße 11, D-69115 Heidelberg, Germany. 
Present address: EMPA, Lerchenfeldstrasse 5, CH-9014 St Gallen, Switzerland.
|
MAIN TEXT |
|---|
|
TOPABSTRACTMAIN TEXTREFERENCES |
|---|
), most of these sequences are highly defective due to mutations or deletions. Only very few human endogenous retroviruses have been shown to express functional proteins, some of which have been hypothesized to play a physiological role either during embryogenesis, in immunosuppression or in antiviral defence (for a review, see Bannert & Kurth, 2004). As yet, only one human endogenous retrovirus, HERV-K, could be shown to produce viral particles, which are expressed in germ-cell tumours and melanomas, although no infectivity could be demonstrated (Boller et al., 1993; Muster et al., 2003).
HERV-K is a multigene family that consists of more than 30 different sequences, of which the oldest entered the human genome more than 40 million years ago. It has been suggested that most HERV-K sequences were raised by germ line reinfection (Belshaw et al., 2004), with HERV-K113 being the provirus that was acquired most recently. HERV-K113 is polymorphic and has a prevalence in the human population of about 30 % (Turner et al., 2001). While in Britain 4 % of the population bears the HERV-K sequence in the genome, the prevalence in eastern Africa is 22 % (Moyes et al., 2005). From these data, it has been calculated that the sequence of HERV-K might have been active less than 100 000 years ago (Turner et al., 2001).
The existence of functional proteins for most viral components of HERV-K has been demonstrated, including the viral protease (Mueller-Lantzsch et al., 1993) and the envelope surface protein (Dewannieux et al. 2005). It has also been shown by morphological and immunological criteria that several different types of HERV-K virus particles are expressed in cell lines established from different germ-cell tumour patients, perhaps derived from different proviruses (Bieda et al., 2001). As yet, it is unclear which of the more than 30 different HERV-K sequences is responsible for production of the virus particles that are produced by germ-cell tumours (Boller et al., 1983; Löwer et al., 1984; Bieda et al., 2001) and melanomas (Muster et al., 2003). Thus, despite the failure to demonstrate infectivity of HERV-K particles, several lines of evidence originating from molecular biology, serology and morphology point to the possibility that a HERV-K variant was active until recently or is still active today. Recently, Heidmann and co-workers (Dewannieux et al., 2006) and, independently, Lee & Bieniasz (2007) have reconstructed the putative progenitor of HERV-K sequences and have demonstrated its infectivity. They pointed out that an infectious HERV-K variant might be generated by recombination of different HERV-K sequences of today. Here, we report that the sequence of HERV-K113 is capable of producing intact particles of retroviral morphology resembling those that are observed in cell lines derived from human germ-cell tumours.
To obtain high-level expression of recombinant HERV-K113, the full-length coding region, except the long terminal repeat (LTR), has been cloned as a proviral cassette downstream of the polyhedrin promoter in a baculovirus expression system. Baculoviruses infect insect cells that show a slightly different glycosylation pattern but mammalian-like splicing (Jeang et al., 1987). For generation of this construct, PCR amplification was performed with a bacterial artificial chromosome (BAC RP11-398B1) (source: Children's Hospital Oakland Research Institute, Oakland, CA, USA) bearing HERV-K113 (GenBank accession no. AY037928
[GenBank]
) using oligonucleotide primers (MWG Biotech) encompassing a ligation-independent (LIC) site for cloning purposes. Oligonucleotides used for PCR were HERV-K113for (5'-GACGACGACAAGATTGGTGCCCAACGTGGAGGC-3'; binding site on the HERV-K113 full-length genome, nt 970–989) and HERV-K113rev (5'-GAGGAGAAGCCCGGTCTACACAGACACAGTAAC-3'; nt 8533–8550).
Gel-purified PCR products were cloned into baculovirus transfer plasmid pBac-2cp EK/LIC (Novagen Merck) and amplified DNA was sequenced (Seqlab). The clone used showed one single amino acid exchange in the env gene region (nt 7146 C to A; proline to histidine) compared with the published sequence of HERV-K113.
The recombinant baculovirus transfer plasmid was co-transfected with BaculoGold DNA (BD Bioscience) using GeneJuice (Novagen Merck) into Sf9 insect cells (Invitrogen) for homologous recombination. Recombinant baculoviruses were harvested and amplified in the course of two rounds of infection using Sf9 cells. The resulting baculovirus stocks were analysed by PCR and subsequently used for protein expression.
Sf9 cells were infected with virus stocks and lysed with Qiagen Shredder for Western blot analyses or fixed with glutaraldehyde for EM analyses 3–5 days post-infection.
In order to obtain a tool for sensitive detection of HERV-K proteins, we developed a panel of monoclonal antibodies (mAbs) to HERV-K viral particles, suitable for immunofluorescence and Western blotting. Initially, BALB/c mice were immunized with either whole formaldehyde-fixed cells or crude preparations of membranes of HERV-K-producing GH teratocarcinoma culture cells (Löwer et al., 1984). After fusion of spleen cells with AG9 myeloma cells, hybridomas were grown in HAT selection medium according to standard methods. Clones were screened by using hybridoma supernatant for immunofluorescence labelling on HERV-K-producing culture cells, leading to a typical fluorescence pattern in the case of a positive clone. Confirmation was done by immunofluorescence double labelling with goat anti-HERV-K antiserum (Boller et al., 1997; Tönjes et al., 1997), by Western blotting and by immunoelectron microscopy. Five different positive clones were obtained, designated HERMA-1, -4, -6, -7 and -8, which turned out to be specific for the Gag protein in HERV-K-expressing human teratocarcinoma cell lines GH and NCCIT (Fig. 1), but not in Jurkat cells, which have been shown not to produce HERV-K proteins (Boller et al., 1997). For subsequent characterization of HERV-K113 produced by insect cells, supernatant of hybridomas was used as such or as an equal mixture of the five clones.
|
; HERMA-6, lanes 1 and 2). When Sf9 cells infected with the Baculo/HERV-K113 construct were analysed, a strong band of 30 kDa was observed that represents the viral Gag capsid protein (Fig. 1b, lane 2). This protein band was not present in cell lysates of Sf9 cells infected with wild-type baculovirus (Fig. 1b, lane 1). Thus, HERV-K113 sequences are specifically expressed by recombinant Sf9 Baculo/HERV-K113. Baculovirus glycoprotein gp64 served as a loading control.
To visualize HERV-K113 expression in Sf9 cells infected with the Baculo/HERV-K113 construct by immunofluorescence, we stained formaldehyde-fixed and Triton X-100-permeabilized cells with the mixture of mAbs to HERV-K Gag protein or with serum of a germ-cell tumour patient followed by FITC-labelled anti-mouse antibody or rhodamine-labelled anti-human antibody, respectively. Analysis by confocal microscopy revealed a speckled pattern around the cells (Fig. 2a), reminiscent of the characteristic labelling pattern in human germ-cell tumour lines (Boller et al., 1997). This indicated expression in the form of viral particles. When a commercially available mAb to HERV-K/Env (Austral Biologicals) was used, no labelling was detected (Fig. 2c), indicating that no glycoproteins are incorporated into viral particles.
|
). By examination of ultrathin sections, retroviral particles were easily detected (Fig. 2e–i). They revealed a structure nearly identical to that observed in the human teratocarcinoma cell line GH. All particles showed the dark electron-dense area between viral core and envelope, characteristic of HERV-K particles (Boller et al., 1983; Bieda et al., 2001), and most particles adhered to the producing cell. No mature particles with condensed core could be observed.
To prove that these particles are encoded specifically by the cloned HERV-K113 sequence, ultrathin frozen sections were prepared and incubated with HERMA mAbs followed by anti-mouse IgG coupled to 10 nm gold particles (Tokuyasu et al., 1981). Examination in the electron microscope showed that recombinant retroviral HERV-K particles were labelled specifically (Fig. 2j).
The ultrastructural appearance of virions, without mature forms with condensed cores, suggests the lack of complete processing of Gag precursors and thus lack of an intact and active protease. Comparison of the protease amino acid sequences of HERV-K113 and HERV-K10 clone pKG-P (Mueller-Lantzsch et al., 1993), which had been used for recombinant protease expression (Schommer et al., 1996), shows three differences within the active HERV-K protease region (aa 179–284) that may account for incomplete activity of the enzyme (Table 1).
|
; Tönjes et al., 1997) and viral RNA derived from purified virus isolates of supernatants of Baculo/HERV-K113-infected Sf9 insect cells (Fig. 1c).
Reverse transcriptase (RT) activity associated with virus-like particles (VLPs) was investigated by employing a PCR-based protocol as established by Silver et al. (1993) and further improved by Lugert et al. (1996). Samples were harvested from tissue-culture supernatants and particulate material was tested. In addition, cell-free membrane-filtered supernatants were tested for RT activity using Mn2+ or Mg2+ in a classical RT activity assay (Cavidi Tech Ab) according to the instructions of the manufacturer. These assays demonstrated no RT activities for purified VLPs produced by the recombinant virus Baculo/HERV-K113 (data not shown).
The polymerase amino acid sequence of HERV-K113 was compared with the polymerase sequence of baculovirus pBac-HERV-K, which demonstrated weak but specific RT activity (Tönjes et al., 1997). The polymerase sequences show a number of differences (Table 1). Both sequences include intact YIDD motifs, but HERV-K113 shows some differences around this motif which may explain the absence of polymerase activity. Particularly, amino acid position 185 is an aspartate (D) in HERV-K113 whereas, in active polymerases of pcGPK31
LTR (Tönjes et al., 1997), HERV-K-Phoenix (Dewannieux et al., 2006) and HERV-K-CON (Lee & Bieniasz, 2007), it is a glutamate (E).
The existence of HERV-K-encoded particles in vivo is well documented (Löwer et al., 1993; Boller et al., 1993). Virions were first characterized in cell lines derived from human germ-cell tumours and characterized by morphological features. Viral proteins have been demonstrated in seminoma and teratocarcinoma tissue, and it is reasonable to assume that particles are produced in these tumours, as a strong and specific immune reaction against HERV-K core and surface proteins can be observed in 67 % of the corresponding patients (Sauter et al., 1995; Boller et al., 1997; Kleiman et al., 2004). The observation of HERV-K particles was also published for melanomas and melanoma cell lines (Muster et al., 2003; Büscher et al., 2006). In vitro, particles with HERV-K-like morphology could repeatedly be observed after expression of HERV-K proviral sequences in baculovirus or cytomegalovirus expression vectors (Tönjes et al., 1997; Dewannieux et al., 2006). However, these proviruses were constructed by prediction of coding-competent sequences and gene engineering. Here, we present for the first time a naturally occurring HERV-K sequence that is capable of producing structurally intact viral particles. It is noteworthy that the HERV-K113 sequence is, in contrast to most other HERV-K sequences, highly polymorphic in the human population and is therefore probably the latest acquired HERV-K sequence during human evolution. It could therefore be speculated that HERV-K113 is responsible for the expression of particles in germ-cell tumour and melanoma patients.
For the putative progenitor of the present HERV-K sequences, infectivity has been shown at a very low level (Dewannieux et al., 2006). The question arises whether HERV-K113 is also infectious. This seems unlikely, because our experiments show the absence of an active RT. In addition, free mature HERV-K113 virions with condensed cores, the morphological equivalent of infectious retroviruses, could not be observed, perhaps because of the lack of functional protease. Moreover, envelope proteins do not seem to be incorporated into viral particles as shown by immunofluorescence, an observation that is congruent with data from Heidmann and co-workers (Dewannieux et al., 2005), who were unable to demonstrate a functional Env of HERV-K113. Therefore, we conclude that HERV-K113, similar to other human endogenous retroviruses, is probably defective.
|
ACKNOWLEDGEMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTMAIN TEXTREFERENCES |
|---|
Belshaw, R., Pereira, V., Katzourakis, A., Talbot, G., Paces, J., Burt, A. & Tristem, M. (2004). Long-term reinfection of the human genome by endogenous retroviruses. Proc Natl Acad Sci U S A 101, 4894–4899.
Bieda, K., Hoffmann, A. & Boller, K. (2001). Phenotypic heterogeneity of human endogenous retrovirus particles produced by teratocarcinoma cell lines. J Gen Virol 82, 591–596.
Boller, K., Frank, H., Löwer, J., Löwer, R. & Kurth, R. (1983). Structural organization of unique retrovirus-like particles budding from human teratocarcinoma cell lines. J Gen Virol 64, 2549–2559.
Boller, K., König, H., Sauter, M., Mueller-Lantzsch, N., Löwer, R., Löwer, J. & Kurth, R. (1993). Evidence that HERV-K is the endogenous retrovirus sequence that codes for the human teratocarcinoma-derived retrovirus HTDV. Virology 196, 349–353.[CrossRef][Medline]
Boller, K., Janssen, O., Schuldes, H., Tönjes, R. R. & Kurth, R. (1997). Characterization of the antibody response specific for the human endogenous retrovirus HTDV/HERV-K. J Virol 71, 4581–4588.
Büscher, K., Hahn, S., Hofmann, M., Trefzer, U., Özel, M., Sterry, W., Löwer, J., Löwer, R., Kurth, R. & Denner, J. (2006). Expression of the human endogenous retrovirus-K transmembrane envelope, Rec and Np9 proteins in melanomas and melanoma cell lines. Melanoma Res 16, 223–234.[CrossRef][Medline]
Dewannieux, M., Blaise, S. & Heidmann, T. (2005). Identification of a functional envelope protein from the HERV-K family of human endogenous retroviruses. J Virol 79, 15573–15577.
Dewannieux, M., Harper, F., Richaud, A., Letzelter, C., Ribet, D., Pierron, G. & Heidmann, T. (2006). Identification of an infectious progenitor for the multiple-copy HERV-K human endogenous retroelements. Genome Res 16, 1548–1556.
Jeang, K. T., Holmgren-Konig, M. & Khoury, G. (1987). A baculovirus vector can express intron-containing genes. J Virol 61, 1761–1764.
Kleiman, A., Senyuta, N., Tryakin, A., Sauter, M., Karseladze, A., Tjulandin, S., Gurtsevitch, V. & Mueller-Lantzsch, N. (2004). HERV-K(HML-2) GAG/ENV antibodies as indicator for therapy effect in patients with germ cell tumors. Int J Cancer 110, 459–461.[CrossRef][Medline]
Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., Doyle, M. & other authors (2001). Initial sequencing and analysis of the human. Nature 409, 860–921.[CrossRef][Medline]
Lee, Y. N. & Bieniasz, P. D. (2007). Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog 3, e10[CrossRef][Medline]
Löwer, R., Löwer, J., Frank, H., Harzmann, R. & Kurth, R. (1984). Human teratocarcinomas cultured in vitro produce unique retrovirus-like viruses. J Gen Virol 65, 887–898.
Löwer, R., Boller, K., Hasenmaier, B., Korbmacher, C., Müller-Lantzsch, N., Löwer, J. & Kurth, R. (1993). Identification of human endogenous retroviruses with complex mRNA expression and particle formation. Proc Natl Acad Sci U S A 90, 4480–4484.
Lugert, R., König, H., Kurth, R. & Tönjes, R. R. (1996). Specific suppression of false-positive signals in the product-enhanced reverse transcriptase assay. Biotechniques 20, 210–217.[Medline]
Medstrand, P., Lindeskog, M. & Blomberg, J. (1992). Expression of human endogenous retroviral sequences in peripheral blood mononuclear cells of healthy individuals. J Gen Virol 73, 2463–2466.
Moyes, D. L., Martin, A., Sawcer, S., Temperton, N., Worthington, J., Griffiths, D. J. & Venables, P. J. (2005). The distribution of the endogenous retroviruses HERV-K113 and HERV-K115 in health and disease. Genomics 86, 337–341.[CrossRef][Medline]
Mueller-Lantzsch, N., Sauter, M., Weiskircher, A., Kramer, K., Best, B., Buck, M. & Grasser, F. (1993). Human endogenous retroviral element K10 (HERV-K10) encodes a full-length gag homologous 73-kDa protein and a functional protease. AIDS Res Hum Retroviruses 9, 343–350.[Medline]
Muster, T., Waltenberger, A., Grassauer, A., Hirschl, S., Caucig, P., Romirer, I., Fodinger, D., Seppele, H., Schanab, O. & other authors (2003). An endogenous retrovirus derived from human melanoma cells. Cancer Res 63, 8735–8741.
Sauter, M., Schommer, S., Kremmer, E., Remberger, K., Dolken, G., Lemm, I., Buck, M., Best, B., Neumann-Haefelin, D. & Mueller-Lantzsch, N. (1995). Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas. J Virol 69, 414–421.
Schommer, S., Sauter, M., Kräusslich, H. G., Best, B. & Mueller-Lantzsch, N. (1996). Characterization of the human endogenous retrovirus K proteinase. J Gen Virol 77, 375–379.
Silver, J., Maudru, T., Fujita, K. & Repaske, R. (1993). An RT-PCR assay for the enzyme activity of reverse transcriptase capable of detecting single virions. Nucleic Acids Res 21, 3593–3594.
Tokuyasu, K. T., Dutton, A. H., Geiger, B. & Singer, S. J. (1981). Ultrastructure of chicken cardiac muscle as studied by double immunolabeling in electron microscopy. Proc Natl Acad Sci U S A 78, 7619–7623.
Tönjes, R. R., Boller, K., Limbach, C., Lugert, R. & Kurth, R. (1997). Characterization of human endogenous retrovirus type K virus-like particles generated from recombinant baculoviruses. Virology 233, 280–291.[CrossRef][Medline]
Turner, G., Barbulescu, M., Su, M., Jensen-Seaman, M. I., Kidd, K. K. & Lenz, J. (2001). Insertional polymorphisms of full-length endogenous retroviruses in humans. Curr Biol 11, 1531–1535.[CrossRef][Medline]
Received 22 October 2007;
accepted 23 October 2007.
This article has been cited by other articles:
|
|
 |
|
  K. Hanke, P. Kramer, S. Seeher, N. Beimforde, R. Kurth, and N. Bannert Reconstitution of the Ancestral Glycoprotein of Human Endogenous Retrovirus K and Modulation of Its Functional Activity by Truncation of the Cytoplasmic Domain J. Virol., December 15, 2009; 83(24): 12790 - 12800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sugimoto and D. J. Schust Review: Human Endogenous Retroviruses and the Placenta Reproductive Sciences, November 1, 2009; 16(11): 1023 - 1033. [Abstract] [PDF]
|
|
|
|
|
|
D. J. Heslin, P. Murcia, F. Arnaud, K. Van Doorslaer, M. Palmarini, and J. Lenz A Single Amino Acid Substitution in a Segment of the CA Protein within Gag That Has Similarity to Human Immunodeficiency Virus Type 1 Blocks Infectivity of a Human Endogenous Retrovirus K Provirus in the Human Genome J. Virol., January 15, 2009; 83(2): 1105 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ruprecht, H. Ferreira, A. Flockerzi, S. Wahl, M. Sauter, J. Mayer, and N. Mueller-Lantzsch Human Endogenous Retrovirus Family HERV-K(HML-2) RNA Transcripts Are Selectively Packaged into Retroviral Particles Produced by the Human Germ Cell Tumor Line Tera-1 and Originate Mainly from a Provirus on Chromosome 22q11.21 J. Virol., October 15, 2008; 82(20): 10008 - 10016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Contreras-Galindo, M. H. Kaplan, P. Leissner, T. Verjat, I. Ferlenghi, F. Bagnoli, F. Giusti, M. H. Dosik, D. F. Hayes, S. D. Gitlin, et al. Human Endogenous Retrovirus K (HML-2) Elements in the Plasma of People with Lymphoma and Breast Cancer J. Virol., October 1, 2008; 82(19): 9329 - 9336. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
